A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md., on Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File)
U.S. health officials are alerting consumers about two more recalls of eyedrops due to contamination risks that could lead to vision problems and serious injury.
The announcements follow a recall last month of eyedrops made in India that were linked to an outbreak of drug-resistant infections. One person died and at least five others had permanent vision loss.
There's no indication the latest recalls are related to those products.
The Food and Drug Administration posted separate recall notices for certain eyedrops distributed by Pharmedica and Apotex after the companies said they are voluntarily pulling several lots of their products from the market. Both companies said the recalls were conducted in consultation with the FDA.
Pharmedica on Friday said it is recalling two lots of Purely Soothing 15% MSM Drops due to problems “that could result in blindness." The over-the-counter drops are designed to treat eye irritation. The Phoenix-based company said consumers should immediately stop using the drops and return them to the place they were purchased.
The recall affects nearly 2,900 bottles, according to the company. The drops were manufactured in Arizona.
Last week, the FDA posted a separate recall announcement from Apotex recalling six lots of prescription eyedrops used to treat a form of glaucoma. The company said it launched the recall after finding cracks in a handful of bottle caps.
The drops are distributed as Brimonidine Tartrate Ophthalmic Solution. 0.15% and were sold between last April through February.
Apotex said in an email that the eyedrops were manufactured in Canada. The company hasn't received any reports of injuries related to the drops.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
As gas prices surge amid the Russian invasion of Ukraine, other nations could potentially transition faster to using clean energy than previously expected. Philip K. Verleger, a senior fellow at the Niskanen Center, joined Cheddar News to explain how this could be a possibility in the near future. "Part of the reason I think we have this invasion and the tantrum that's being thrown by Russia, terrible tantrum, is because the Russians were trying to slow down the transition," he said. "Ironically they speeded it up."
As Russia intensifies its war on Ukraine, President Biden announced a ban on oil imported from the aggressor nation. Critics of Russia have said this would be the best way to force Putin to pull back, but curbs on Russian oil exports are expected to send already skyrocketing oil and gas prices even higher, further impacting consumers, businesses, financial markets, and the global economy. Leslie Beyer, CEO of the Energy Workforce and Technology Council, joined Cheddar News' Closing Bell to discuss. "It's certainly going to increase pricing, but it is the right thing to do," she said. "The industry itself has already pulled out of the significant portion of its operations in Russia."
On this episode of Cheddar Innovates: Vision Marine Technologies CEO discusses how e-boats will play a role in the fight against the climate crisis; Lasso CEO breaks down how the design behind these compression socks can prevent injuries and improve performance; Cheddar gets a look at Curiosity Stream's 'The Tombs Of Egypt.'
Vaccine maker Pfizer delayed its COVID shot for kids allegedly due to a lack of data on how it would perform against the omnicron variant, according to the Wall Street Journa. Peter Pitts, professor and founder of the Center for Medicine in the Public Interest and a former FDA associate commissioner, joined Cheddar News Wrap to break down why the authorization can't be rushed. "Going forward, the FDA wants to look at data specifically against omicron, and it looks like that's going to be a three-shot regimen versus two, which was efficient against delta but not omicron because obviously omicron is more infectious," said Pitts.
Walker Ross, Assistant Professor of Sports Business Management at Florida Southern College, joins Business of Sports: The Beijing Winter Olympics 2022, where he says that actions Beijing and other Olympic host sites have been implementing to combat climate change has simply not been enough to offset their carbon footprint.
Bamboo-based toilet paper company Cloud Paper raised $5 million in a recent funding round. Its product is a bamboo-based alternative to traditional toilet paper made from trees, and its mission is to end the deforestation caused by traditional paper products. Cloud Paper says the raise will allow it to make significant investments in its supply chain, product development, and hiring. Ryan Fritsch, a co-founder of Cloud Paper, joined Cheddar News' Closing Bell to discuss.
Space tourism company World View plans to launch its first commercial flights in early 2024, with voyages to take off from iconic locations around the world like the Grand Canyon — but seemingly at a flexible price point. Dale Hipsh, president of tourism and exploration at World View, joined Cheddar to discuss what a trip to the stratosphere would look like with his company and its much less expensive take on space travel. "Our technology allows us to be more democratic, to offer more opportunities for people to experience near space, and that overview effect," he said. "So we're really thrilled to be bringing it to market."
A recent NOAA report found America's coastline could experience a century's worth of sea rise in just 30 years. By 2050, water on the U.S. coast will be 10-12 inches higher, causing major eastern cities to be hit regularly with floods, even on sunny days. Gary Mitchum, professor of physical oceanography at the University of South Florida, joins Cheddar News to discuss.
The Biden administration is launching a new task force to promote the use of 'cleaner' construction materials with lower life cycle emissions. This comes as the White House works to speed up government purchases of greener products. Sweta Chakraborty, climate change expert and U.S. president of "We Don't Have Time," joins Cheddar News to discuss.
Stephen Gardner, director at ETF Managers Group, explains why investors shouldn't be rushing to sell vaccine stocks like Moderna or BioNTech even as the spread of COVID-19 slows down.
